Filipa Antunes, a researcher at ICVS, has won the ART 3R Award for 2025. Her project, “Intranasal Administration as a Minimally Invasive Alternative for Stem Cell-Based Parkinson’s Disease Therapy in Rodents,” has been awarded a €3,000 grant to explore a more humane and cost-effective method for treating Parkinson’s disease in animal models.

ICVS is a contributing partner in the launch of GALActIC, a pioneering European Union research project aimed at tackling Influenza-associated Pulmonary Aspergillosis (IAPA). The study, led by a European consortium, is funded by the European Partnership for Personalised Medicine (EP PerMed) and promises to pave the way for more effective identification and treatment of this severe condition.

Researchers from ICVS and INL have developed an innovative multi-channel electrical stimulator designed to advance in vitro cellular research. This innovative device enables precise electrical stimulation of cells, promoting axonal growth and guiding stem cell differentiation, key processes in regenerative medicine and therapy development.

ICVS Researcher Nuno Dinis Alves Explored the Role of Gut Serotonin in Treating Depression and Anxiety While Reducing Side Effects of Classic Antidepressants

Three researchers from ICVS have been awarded ESCMID grants for their research into infectious diseases and immunology. João do Canto Gomes, Samuel Gonçalves and Vitória Baptista will receive support to advance their innovative projects.

ICVS researcher Tiago Gil Oliveira has been awarded the 2024 BIAL Clinical Medicine Award for his groundbreaking work in Alzheimer’s disease research. His project, titled “Unveiling the Mysteries of the Brain’s Regional Susceptibility to Neurodegeneration in Alzheimer’s Disease: From Neuropathology to Brain Magnetic Resonance Imaging,” identifies the specific regions of the brain most affected by Alzheimer’s, offering hope for earlier diagnosis and more effective treatments.